| Literature DB >> 26549248 |
Sahar Kohanim1, Sotiria Palioura2, Hajirah N Saeed3, Esen K Akpek4, Guillermo Amescua2, Sayan Basu5, Preston H Blomquist6, Charles S Bouchard7, John K Dart8, Xiaowu Gai3, José A P Gomes9, Darren G Gregory10, Geetha Iyer11, Deborah S Jacobs12, Anthony J Johnson13, Shigeru Kinoshita14, Iason S Mantagos15, Jodhbir S Mehta16, Victor L Perez2, Stephen C Pflugfelder17, Virender S Sangwan5, Kimberly C Sippel18, Chie Sotozono14, Bhaskar Srinivasan11, Donald T H Tan16, Radhika Tandon19, Scheffer C G Tseng20, Mayumi Ueta14, James Chodosh21.
Abstract
The intent of this review is to comprehensively appraise the state of the art with regard to Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), with particular attention to the ocular surface complications and their management. SJS and TEN represent two ends of a spectrum of immune-mediated, dermatobullous disease, characterized in the acute phase by a febrile illness followed by skin and mucous membrane necrosis and detachment. The widespread keratinocyte death seen in SJS/TEN is rapid and irreversible, and even with early and aggressive intervention, morbidity is severe and mortality not uncommon. We have divided this review into two parts. Part I summarizes the epidemiology and immunopathogenesis of SJS/TEN and discusses systemic therapy and its possible benefits. We hope this review will help the ophthalmologist better understand the mechanisms of disease in SJS/TEN and enhance their care of patients with this complex and often debilitating disease. Part II (April 2016 issue) will focus on ophthalmic manifestations.Entities:
Keywords: apoptosis; drug-induced disease; immune-mediated disease; keratinocyte death Stevens-Johnson Syndrome; toxic epidermal necrolysis
Mesh：
Year: 2015 PMID： 26549248 DOI： 10.1016/j.jtos.2015.10.002
Source DB: PubMed Journal: Ocul Surf ISSN： 1542-0124 Impact factor: 5.033